Harbour Biomed in antibody deal with ImmunoChina

Harbour BioMed (Shanghai, China) granted ImmunoChina Pharmaceuticals Co. Ltd. rights to human antibody fragments discovered through its H2L2 transgenic mouse platform for use in developing chimeric antigen receptor (CAR) T cell therapies. Harbour's H2L2 mice generate human mAbs with both heavy and light chains...